Drug information of Meropenem

Meropenem

Drug group: Carbapenems

Meropenem is an antibiotic that fights bacteria. Meropenem is used to treat severe infections of the skin or stomach. Meropenem is also used to treat bacterial meningitis (infection of brain or spinal cord).

Mechanism of effect

Meropenem is an antibacterial drug. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets.

Pharmacodynamic

Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.

Pharmacokinetics

Protein binding: Approximately 2%.Primarily excreted unchanged. There is one metabolite which is microbiologically inactive. Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, Half life:Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.

Dosage

Adult Patients The recommended dose of Meropenem for injection (I.V.) is 500 mg given every 8 hours for skin and skin structure infections and 1 g given every 8 hours for intra-abdominal infections. Meropenem for injection (I.V.) should be administered by intravenous infusion over approximately 15 to 30 minutes. Doses of 1 g may also be administered as an intravenous bolus injection (5 to 20 mL) over approximately 3-5 minutes. Use in Pediatric Patients (≥ 3 Months only) For pediatric patients from 3 months of age and older, the Meropenem for injection (I.V.) dose is 10, 20 or 40 mg/kg every 8 hours (maximum dose is 2 g every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis) Pediatric patients weighing over 50 kg should be administered Meropenem as adults.

Alerts

1-Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. 2-Seizures and other adverse CNS experiences have been reported during treatment with Meropenem for injection (I.V.) These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and/or compromised renal function. 3-Case reports in the literature have shown that co-administration of carbapenems, including Meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. 4-Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Meropenem for injection (I.V.)

Points of recommendation

1-Dosage adjustment is necessary in patients with creatinine clearance 50 mL/min or less . 2-Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Pregnancy level

B

Related drugs

Imipenem , ertapenem , Doripenem


Ask a Pharmacist


User's questions
    No comments yet.